Richard Rosenquist

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

Somatic hypermutation and V(H) gene usage in mantle cell lymphoma.

Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia.

A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma.

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma.

Genetic counselling for cancer and risk perception.

V(H)3-21 gene usage in chronic lymphocytic leukemia--characterization of a new subgroup with distinct molecular features and poor survival.

Rheumatoid arthritis and malignant lymphomas.

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.

Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia.

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.

Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia.

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.

Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.

Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis.

What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas.

Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma.

Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.

TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.

Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays.

Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios.

Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.

Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.

Cancer genetic counselees' self-reported psychological distress, changes in life, and adherence to recommended surveillance programs 3-7 years post counseling.

In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.

Quantification of normal cell fraction and copy number neutral LOH in clinical lung cancer samples using SNP array data.

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.

Does enhanced information at cancer genetic counseling improve counselees' knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives?--a randomized study.

Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity.

Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen.

A hypothesis-generating search for new genetic breast cancer syndromes--a national study in 803 Swedish families.

IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.

Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006.

Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.

High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Disclosing cancer genetic information within families: perspectives of counselees and their at-risk relatives.

Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.

Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma.

High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival.

Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

What information do cancer genetic counselees prioritize?

RNA-based markers as prognostic factors in chronic lymphocytic leukemia.

Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.

Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia.

Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.

Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection.

Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia.

Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles.

Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies.

Uncovering the DNA methylome in chronic lymphocytic leukemia.

Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.

Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.

ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.

Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence.

Antigen selection in B-cell lymphomas--tracing the evidence.

DNA repair genes are selectively mutated in diffuse large B cell lymphomas.

Antigens in lymphoma development--current knowledge and future directions.

A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.

Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.

IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?

The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells.

microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.

Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia.

A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.

Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.

Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.

Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Molecular evidence for antigen drive in the natural history of mantle cell lymphoma.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.

A new piece to the stereotypy "puzzle" in chronic lymphocytic leukemia.

Prognostic relevance of MYD88 mutations in CLL: the jury is still out.

Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia.

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference.

Not all subclones matter in CLL.

Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2.

The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.

B-cell malignancies: All roads lead to NF-κB activation.

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.

Massive and parallel expression profiling using microarrayed single-cell sequencing.

Unraveling the DNA Methylome in Mantle Cell Lymphoma: New Insights into the Cellular Origin.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma.

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia.

Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact.

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.

Clinical and functional impact of recurrent mutations in mantle cell lymphoma.

A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Introduction: Epigenetics in cancer.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia.